Jeena Sikho Lifecare Limited (JSLL) Earnings Call Transcript & Summary

Ladies and gentlemen, good day, and welcome to the Jeena Sikho Lifecare Limited H1 FY '25 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Ranvir Singh from Nuvama Wealth. Thank you, and over to you, sir.

Yes. Thank you, moderator. So on behalf of Jeena Sikho Lifecare Limited, I extend a very warm welcome to all participants on H1 FY '25 financial results discussion Call. Today on our call, we have Mr. Manish Grover-ji, Managing Director; and Mr. Nanak Chand-ji, the CFO. Before beginning with this call, I would like to give a short disclaimer. So this call may contain some of the forward-looking statements, which are completely based upon the management's belief, opinion and expectations as of today. These statements are not a guarantee of company's future performance and involve unforeseen risk and uncertainty. With this, I would have to hand over the call to Mr. Manish-ji for his opening remarks. Over to you, sir, Manish-sir.

[Foreign Language]

Good afternoon, everyone. Thank you, Manish sir. As mentioned by Manish sir, we have achieved the health financial performance during the H1 FY '25. Here are some key highlights. We generated revenue from operation and grew by 36% on a year-on-year basis to INR 214 crores, mainly driven by the hospital services, which has grew by 72% Y-o-Y basis, that is INR 114 crores. While product sales grew by 10% to INR 100 crores, the EBITDA during the H1 FY '25 grew by 32% Y-o-Y basis to INR 59.28 crores by implementing the EBITDA margin, 28%. The H1 FY '25 PAT grew by 47% Y-o-Y basis to INR 46.88 crores. We retain a healthy balance sheet with net cash and equivalent of INR 69 crores by end of the H1 FY '25. Our ex-cash ROCE stood 82%, respectively. And we also spent the INR 16.72 crores in CapEx H1 FY '25. Thank you so much.

Sir, should we open the floor for questions?

You can open floor for questions.

[Operator Instructions] Our first question comes from [ Sagar Jain ], individual investor.

Congratulations, Manish and Nanak, for posting the very good results. However, I just have one question regarding the expansion that you are already expanding into the 21 states of India and you have already crossed more than 100 towns of India. So I just want to know that how this revenue being generated is majorly from the few hospitals or it's evenly distributed, how it is? Like it's coming from few locations of India or it is coming from every part of the 100 hospitals or maybe hospitals in 100 towns it's coming from. So how it is distributed?

[Foreign Language]

[Foreign Language] Really thanks, sir. Even I am also a diabetic patient, so I definitely wish to...

[Foreign Language]

Absolutely, sir. I can see you and team are very aggressively [Audio Gap] grow our business.

The next question comes from Sumit Gupta from Centrum.

I have two questions. First is on the hospital side. So the kind of expansion that you are going to do, just want to understand on the doctor cost point. So how many doctors do you plan to -- like overall doctors strength, how much do you plan to increase and [Foreign Language] overall?

[Foreign Language]

Understood, sir. And sir, going forward, like as I'm seeing from FY '23, your government revenue as a percentage of overall revenue it has increased from 12% to 24%, which means it doubled. So going forward also, what kind of government empanelment...

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Chirag from White Pine.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from [ Yash ] from Stallion Asset.

[Foreign Language]

[Foreign Language]

The next question comes from [ Prerna ] from Shome Partnership Limited.

Congratulations for a good set of numbers. [Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Volume growth in medicines increased by 10% and in the service sectors, increased by 42% to 53%. In which way? Volume?

Okay. Okay. Sir, just the last question is [Foreign Language].

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from [ K. Rajesh ], individual investor.

Congratulations for very good set of numbers. And I think we are going as per...

Sorry to interrupt, Mr. Rajesh, you're sounding a bit muffled, if you can use the handset, please?

Sir, I think, as per the numbers, we are going as per the guidance of INR 450 crores. And can we expect INR 1,000 crores revenue in FY '26, sir? As per the bed occupancy, it is also increasing.

FY '26 [Foreign Language].

Sir, what about the main Board plan? Are they going on line...

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Dubai, Vietnam, Mauritius, London, America, Australia, New Zealand [Foreign Language].

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Nishant Gupta from Minerva Global Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Anurag Agarwal from Multify Wealth.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Akshay from CD Integrated Services Limited.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Operator Instructions] The next question comes from Isha from VT Capital.

Congratulations on a good set of numbers. [Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Priyam Khimawat from ASK Investment Managers.

[Foreign Language] Is it kidney? Is it liver? What is it?

[Foreign Language]

[Foreign Language]

[Foreign Language]

Exactly, exactly. [Foreign Language]

[Foreign Language]

Got it, got it. [Foreign Language]

[Foreign Language]

So on an average, if a doctor is having 10-year or 5-year experience, what kind of annual income do they make?

[Foreign Language]

[Foreign Language]

[Foreign Language]

Okay, sir. Got it, got it. All the best, Acharya-ji. You're doing great job. Congratulations. And continue doing the great job going ahead.

Thank you, sir. Thank you. [Foreign Language]

Next question comes from Amit Jeswani from Stallion Asset Private Limited.

[Foreign Language] I have no doubt on your capabilities, but [Foreign Language] but still how you're managing your time?

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

The next question comes from Akshay from CD Integrated Services Limited.

[Foreign Language]

[Foreign Language]

[Foreign Language] All the best for the future.

The next question comes from [ Nitin Gupta ], an individual investor.

[Foreign Language] To fund expansions, do you have any plan to raise funds in future or everything can be funded by internal accruals?

[Foreign Language]

[Foreign Language]

[Foreign Language]

As there are no further questions from the participants, I now hand the conference over to the management for closing comments. Manish sir, you can give the closing remarks, if there are any.

[Foreign Language] Thank you.

Thank you. On behalf of Jeena Sikho Lifecare Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.